 Bolt Biotherapeutics Inc NASDAQ: BOLT announced the presentation of interim clinical data from its Phase 12 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate ISAC comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to an innovative TLR78 agonist. 